Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc.
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
This new kind of flu shot by Moderna has just been approved by the FDA
Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine
Moderna Stock Climbs on Flu Vaccine Approval
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future
Sandisk, AppLovin, Moderna, and More Stocks That Explain Today's Market
FDA Approves First mRNA Flu Vaccine For Older Adults
The Food and Drug Administration approved Moderna's mRNA flu vaccine, the first of its kind, capping a review that nearly collapsed in February.
US FDA approves first mRNA flu shot from Moderna
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
Cetera Investment Advisers Has $4.13 Million Stake in Moderna, Inc. $MRNA
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now